Abstract
The pyrrolizidine alkaloid monocrotaline produces pulmonary hypertension by an as yet unknown mechanism (1). The possibility that inappropriate angiotensin converting enzyme (ACE) activity may contribute to monocrotaline-induced lung injury led to this study of ACE inhibitors as modifying agents in monocrotaline-treated rats.